NDAORALTABLETPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Clinical Trials (5)
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Started Oct 2024
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Started Jul 2023
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Started Jul 2023
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Started Sep 2021
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Started Jan 2021
43 enrolled
Advanced and Metastatic Urothelial Cancer
Loss of Exclusivity
LOE Date
Nov 5, 2039
166 months away
Patent Expiry
Nov 5, 2039
Exclusivity Expiry
Sep 30, 2029
Company
Taiho Oncology
NJ - Princeton